NASDAQ | VICL: 1.27  +0.01

DNA Technology

Vical's proprietary core technology is based on plasmid DNA (pDNA), closed loops of DNA that encode any protein of interest. When injected into tissues such as skeletal muscle or the skin, cells take up pDNA and produce the encoded protein. This allows for pDNA to be used as the basis for a broad range of biopharmaceutical products: infectious disease vaccines (delivering antigens from viruses, bacteria, or parasites), cancer vaccines or immunotherapeutics (delivering tumor antigens or immunostimulatory proteins), and growth factors to stimulate angiogenesis and tissue repair in diseases such as cardiovascular disorders.

Since its initial discovery, Vical has continued to improve its DNA delivery technology so as to maximize gene expression as well as the body's response to the proteins produced. For example, we optimize the DNA sequences that make up our pDNA, and we continue to develop new formulation and delivery technologies, including the use of lipid molecules (which can function as vaccine adjuvants) and synthetic polymers such as poloxamers.


P. 858 646 1100 10390 Pacific Center Court, San Diego, California 92121
Designed by Mentus
This link to a non-Vical website is provided as a resource. Vical assumes no responsibility for content not provided by Vical, or for practices or standards of any non-Vical websites.